洛美他派不会改变纯合子家族性高胆固醇血症患者的前蛋白转化酶枯草溶菌素9（PCSK9）和脂蛋白(a) [Lp(a)]水平：细胞因子和血脂谱分析
Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile.
作者信息
Lupo Maria Giovanna, Arcidiacono Diletta, Zaramella Alice, Fimiani Fabio, Calabrò Paolo, Cefalù Angelo Baldassare, Averna Maurizio, D'Erasmo Laura, Arca Marcello, De Martin Sara, Zambon Alberto, Ferri Nicola
机构信息
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padua, Italy.
Digestive Endoscopy Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
出版信息
Atheroscler Plus. 2021 Jun 19;43:7-9. doi: 10.1016/j.athplu.2021.05.001. eCollection 2021 Sep.
Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.
洛美他派是一种用于治疗纯合子家族性高胆固醇血症患者的药物，它降低了总胆固醇和低密度脂蛋白胆固醇，但未观察到前蛋白转化酶枯草溶菌素9（PCSK9）和脂蛋白（a）[Lp(a)]血浆水平有显著变化。还观察到一些炎症介质的变化，包括超敏C反应蛋白（hsCRP），这可能提示其具有抗炎作用。
Zotero 插件